X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1048) 1048
humans (823) 823
type 2 diabetes (716) 716
dpp-4 inhibitor (647) 647
diabetes mellitus, type 2 - drug therapy (637) 637
dpp-4 inhibitors (587) 587
diabetes (498) 498
endocrinology & metabolism (487) 487
male (477) 477
dipeptidyl-peptidase iv inhibitors - therapeutic use (418) 418
sitagliptin (394) 394
hypoglycemic agents - therapeutic use (377) 377
glucagon-like peptide-1 (365) 365
female (361) 361
animals (320) 320
middle aged (318) 318
pharmacology & pharmacy (304) 304
glucose (302) 302
metformin (302) 302
dipeptidyl peptidase-4 inhibitor (276) 276
double-blind (276) 276
dpp-4 (261) 261
glycemic control (256) 256
aged (247) 247
treatment outcome (244) 244
vildagliptin (237) 237
type 2 diabetes mellitus (232) 232
diabetes mellitus (231) 231
dipeptidyl-peptidase iv inhibitors - pharmacology (231) 231
glp-1 (226) 226
insulin (211) 211
diabetes mellitus, type 2 - blood (207) 207
type-2 diabetes-mellitus (202) 202
hypoglycemic agents (199) 199
safety (199) 199
adult (192) 192
linagliptin (191) 191
dipeptidyl peptidase-4 inhibitors (190) 190
dipeptidyl-peptidase iv inhibitors - adverse effects (178) 178
drug therapy (173) 173
hypoglycemic agents - adverse effects (171) 171
efficacy (169) 169
adamantane - analogs & derivatives (168) 168
diabetes therapy (166) 166
blood glucose - drug effects (164) 164
dextrose (163) 163
analysis (162) 162
care and treatment (161) 161
internal medicine (159) 159
drug therapy, combination (158) 158
blood glucose - metabolism (157) 157
beta-cell function (155) 155
hypoglycemic agents - administration & dosage (149) 149
dipeptidyl peptidase 4 - metabolism (141) 141
saxagliptin (140) 140
mellitus (139) 139
hypoglycemic agents - pharmacology (138) 138
dipeptidyl-peptidase iv inhibitors - administration & dosage (136) 136
medicine & public health (135) 135
mice (133) 133
glucagon (132) 132
incretin (129) 129
double-blind method (125) 125
glycated hemoglobin a - metabolism (125) 125
improves glycemic control (124) 124
sitagliptin phosphate (123) 123
hypoglycemia (120) 120
rats (120) 120
medicine, general & internal (119) 119
pharmacokinetics (113) 113
risk factors (113) 113
diabetes mellitus, type 2 - complications (112) 112
research (110) 110
peptidase (109) 109
review (108) 108
incretins (105) 105
clinical trials (102) 102
therapy (101) 101
peptides (99) 99
hyperglycemia (98) 98
diabetes mellitus, type 2 - metabolism (97) 97
metformin - therapeutic use (97) 97
adamantane - therapeutic use (95) 95
cardiac & cardiovascular systems (95) 95
insulin resistance (94) 94
chemistry, medicinal (93) 93
glycosylated hemoglobin (92) 92
oxidative stress (92) 92
glp-1 receptor agonists (88) 88
medicine, research & experimental (88) 88
alogliptin (86) 86
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (86) 86
dosage and administration (85) 85
liraglutide (85) 85
health aspects (84) 84
biochemistry & molecular biology (83) 83
dipeptidyl peptidase-4 (83) 83
dpp-4 inhibition (83) 83
mortality (81) 81
drug-naive patients (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1606) 1606
French (23) 23
Japanese (22) 22
German (19) 19
Czech (11) 11
Spanish (10) 10
Korean (8) 8
Russian (5) 5
Polish (4) 4
Chinese (3) 3
Hungarian (2) 2
Slovak (2) 2
Arabic (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk... 
cardiovascular disease | type 2 diabetes | DPP | hypoglycaemia | dapagliflozin | diabetes complications | 4 inhibitor | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | DPP‐4 inhibitor | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
Background: Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with... 
heart failure | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | death | observational studies | SGLT-2 inhibitor | CARDIAC & CARDIOVASCULAR SYSTEMS | SEVERE HYPOGLYCEMIA | SULFONYLUREA | INITIATION | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Data bases | Matching | Confidence intervals | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 195 - 199
Journal Article
Journal Article
Journal Article
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 09/2017, Volume 5, Issue 9, pp. 709 - 717
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 07/2014, Volume 13, Issue 1, pp. 110 - 110
Background: Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with... 
Dipeptidyl peptidase 4 (DPP-4) inhibitors | Endothelial function | Flow-mediated dilatation | Alpha glucosidase inhibitor | CD34 | PROGENITOR CELLS | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | VASCULAR-DISEASE | FLOW-MEDIATED VASODILATION | GLUCAGON-LIKE PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | CARDIOVASCULAR-DISEASE | JAPANESE PATIENTS | CORONARY-ARTERY-DISEASE | Prospective Studies | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Endothelium, Vascular - drug effects | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Pyrazines - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Endothelium, Vascular - physiology | Young Adult | Inositol - therapeutic use | Aged, 80 and over | Adult | Female | Sitagliptin Phosphate | Triazoles - therapeutic use | Inositol - pharmacology | Glycoside Hydrolase Inhibitors - pharmacology | Inositol - analogs & derivatives | Triazoles - pharmacology | Diabetes Mellitus, Type 2 - diagnosis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Pyrazines - pharmacology | Urine | Oxidative stress | Peptides | Internal medicine | Colleges & universities | Cardiovascular disease | Dentistry | Medicine | Hyperglycemia | Hospitals | Coronary vessels | Diabetes | Acute coronary syndromes | Drug dosages | Pharmaceutical sciences | Pharmaceuticals | Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2012, Volume 167, Issue 2, pp. 451 - 457
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 10/2012, Volume 20, Issue 19, pp. 5705 - 5719
Journal Article